Last reviewed · How we verify
NCT02292472
Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy
Phase 2 trial testing Botulinum Toxin Type A in Hypertrophy of Masseter Muscle in 69 participants. Completed in 24 August 2015.
24 May 2015
Quick facts
| Lead sponsor | Medy-Tox |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 6 October 2014 |
| Primary completion | 24 May 2015 |
| Estimated completion | 24 August 2015 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Botulinum Toxin Type A (BOTULINUM TOXIN TYPE A) — full drug profile →
- Placebos — full drug profile →
Conditions studied
- Hypertrophy of Masseter Muscle — all drugs for Hypertrophy of Masseter Muscle →
Sponsor
Medy-Tox — full company profile →
Who can join
19 and older, any sex, with Hypertrophy of Masseter Muscle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02292472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botulinum Toxin Type A
Trials testing the same drug.
- NCT06974617 — Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine · NA · recruiting
- NCT04965311 — Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatecto · Phase 2 · terminated
- NCT06562023 — Botulinum Toxin and Mesotherapy on Enhancement of Facial Scarring · NA · completed
- NCT04073303 — BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence · Phase 3 · completed
- NCT03747900 — Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity · NA · completed
Other Medy-Tox trials
Trials by the same sponsor.
- NCT05195112 — Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 3 · completed
- NCT04157686 — MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) · Phase 3 · completed
- NCT04281745 — Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® · Phase 4 · unknown
- NCT04144049 — A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 2 · completed
- NCT04143854 — Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02292472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medy-Tox
- Last refreshed: 27 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02292472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing